Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: A commentary from a Kidney Disease: Improving Global Outcomes controversies conference

Markus Ketteler; Grahame J. Elder; Pieter Evenepoel; Joachim H. Ix; Sophie A. Jamal; Marie Hélène Lafage-Proust; Rukshana Shroff; Ravi I. Thadhani; Marcello A. Tonelli; Bertram L. Kasiske; David C. Wheeler; Mary B. Leonard

doi:10.1038/ki.2014.425

Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: A commentary from a Kidney Disease: Improving Global Outcomes controversies conference

Markus Ketteler, Grahame J. Elder, Pieter Evenepoel, Joachim H. Ix, Sophie A. Jamal, Marie Hélène Lafage-Proust, Rukshana Shroff, Ravi I. Thadhani, Marcello A. Tonelli, Bertram L. Kasiske, David C. Wheeler, Mary B. Leonard

Medicine - Renal and Hypertension Division

Research output: Contribution to journal › Article › peer-review

114 Scopus citations

Abstract

A new definition and classification of chronic kidney disease-mineral and bone disorder (CKD-MBD) was proposed in 2005 and it was later followed by a guideline publication on this topic from Kidney Disease: Improving Global Outcomes (KDIGO) in 2009. This work recognized that CKD-MBD is a syndrome of bone abnormalities, laboratory abnormalities, and vascular calcification linked to fractures, cardiovascular disease, and mortality. Because of limited data at the time of the original guideline systematic review, many of the recommendations were cautiously vague. KDIGO convened a Controversies Conference in October 2013 to review the CKD-MBD literature published since the 2009 guideline. Specifically, the objective of this conference was to determine whether sufficient new data had emerged to support a reassessment of the CKD-MBD guideline and if so to determine the scope of these potential revisions. This report summarizes the results of these proceedings, highlighting important new studies conducted in the interval since the original KDIGO CKD-MBD guideline.

Original language	English (US)
Pages (from-to)	502-508
Number of pages	7
Journal	Kidney international
Volume	87
Issue number	3
DOIs	https://doi.org/10.1038/ki.2014.425
State	Published - Mar 1 2015

Bibliographical note

Funding Information:
MK declared having received consultancy fees and speaker honoraria from Abbvie, Amgen, Fresenius, Medice, Mitsubishi, Sanofi, Shire, and Vifor. GJE declared having received consultancy fees from Amgen, Shire, and Vifor Australia; speaker honoraria from Amgen, Sanofi and Shire. PE declared having received consultancy fees from Amgen; speaker honoraria from Amgen, Astellas, Fresenius, and Shire; research support from Amgen. JHI declared having received consultancy fees from AstraZeneca and Keryx; speaker honoraria from Shire. SAJ declared having received consultancy fees from Amgen and Sanofi; speaker honoraria from Amgen, Bayer, Sanofi/Genzyme, and Warner Chilcott/Actavis. MHLP declared having received research support from Servier. RIT declared having received consultancy fees from Fresenius and research support from Kaneka. MAT declared having received research support from Abbott Laboratories through a peer reviewed grant to the Canadian Institutes of Health Research. DCW declared having received consultancy fees from Abbvie, Amgen, Astellas, Baxter, F Hoffmann-La Roche, Janssen, Merck Sharp & Dohme, Otsuka, and Vifor; research funding from AstraZeneca/British Heart Foundation, Kidney Research UK, Medical Research Council, Healthcare Quality Improvement Partnership; speaker honoraria from Amgen and Otsuka. BLK, MBL and RS reported no relevant disclosures.

Publisher Copyright:
© 2014 International Society of Nephrology.

Keywords

CKD-MBD
PTH
calcium
clinical practice guideline
phosphate
renal osteodystrophy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1038/ki.2014.425

Find It

Find It at U of M Libraries

Cite this

Ketteler, M., Elder, G. J., Evenepoel, P., Ix, J. H., Jamal, S. A., Lafage-Proust, M. H., Shroff, R., Thadhani, R. I., Tonelli, M. A., Kasiske, B. L., Wheeler, D. C., & Leonard, M. B. (2015). Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: A commentary from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney international, 87(3), 502-508. https://doi.org/10.1038/ki.2014.425

Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: A commentary from a Kidney Disease: Improving Global Outcomes controversies conference. / Ketteler, Markus; Elder, Grahame J.; Evenepoel, Pieter et al.
In: Kidney international, Vol. 87, No. 3, 01.03.2015, p. 502-508.

Research output: Contribution to journal › Article › peer-review

Ketteler, M, Elder, GJ, Evenepoel, P, Ix, JH, Jamal, SA, Lafage-Proust, MH, Shroff, R, Thadhani, RI, Tonelli, MA, Kasiske, BL, Wheeler, DC & Leonard, MB 2015, 'Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: A commentary from a Kidney Disease: Improving Global Outcomes controversies conference', Kidney international, vol. 87, no. 3, pp. 502-508. https://doi.org/10.1038/ki.2014.425

@article{7b45403d59f64e1eb0841cbe6848724b,

title = "Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: A commentary from a Kidney Disease: Improving Global Outcomes controversies conference",

abstract = "A new definition and classification of chronic kidney disease-mineral and bone disorder (CKD-MBD) was proposed in 2005 and it was later followed by a guideline publication on this topic from Kidney Disease: Improving Global Outcomes (KDIGO) in 2009. This work recognized that CKD-MBD is a syndrome of bone abnormalities, laboratory abnormalities, and vascular calcification linked to fractures, cardiovascular disease, and mortality. Because of limited data at the time of the original guideline systematic review, many of the recommendations were cautiously vague. KDIGO convened a Controversies Conference in October 2013 to review the CKD-MBD literature published since the 2009 guideline. Specifically, the objective of this conference was to determine whether sufficient new data had emerged to support a reassessment of the CKD-MBD guideline and if so to determine the scope of these potential revisions. This report summarizes the results of these proceedings, highlighting important new studies conducted in the interval since the original KDIGO CKD-MBD guideline.",

keywords = "CKD-MBD, PTH, calcium, clinical practice guideline, phosphate, renal osteodystrophy",

author = "Markus Ketteler and Elder, {Grahame J.} and Pieter Evenepoel and Ix, {Joachim H.} and Jamal, {Sophie A.} and Lafage-Proust, {Marie H{\'e}l{\`e}ne} and Rukshana Shroff and Thadhani, {Ravi I.} and Tonelli, {Marcello A.} and Kasiske, {Bertram L.} and Wheeler, {David C.} and Leonard, {Mary B.}",

note = "Funding Information: MK declared having received consultancy fees and speaker honoraria from Abbvie, Amgen, Fresenius, Medice, Mitsubishi, Sanofi, Shire, and Vifor. GJE declared having received consultancy fees from Amgen, Shire, and Vifor Australia; speaker honoraria from Amgen, Sanofi and Shire. PE declared having received consultancy fees from Amgen; speaker honoraria from Amgen, Astellas, Fresenius, and Shire; research support from Amgen. JHI declared having received consultancy fees from AstraZeneca and Keryx; speaker honoraria from Shire. SAJ declared having received consultancy fees from Amgen and Sanofi; speaker honoraria from Amgen, Bayer, Sanofi/Genzyme, and Warner Chilcott/Actavis. MHLP declared having received research support from Servier. RIT declared having received consultancy fees from Fresenius and research support from Kaneka. MAT declared having received research support from Abbott Laboratories through a peer reviewed grant to the Canadian Institutes of Health Research. DCW declared having received consultancy fees from Abbvie, Amgen, Astellas, Baxter, F Hoffmann-La Roche, Janssen, Merck Sharp & Dohme, Otsuka, and Vifor; research funding from AstraZeneca/British Heart Foundation, Kidney Research UK, Medical Research Council, Healthcare Quality Improvement Partnership; speaker honoraria from Amgen and Otsuka. BLK, MBL and RS reported no relevant disclosures. Publisher Copyright: {\textcopyright} 2014 International Society of Nephrology.",

year = "2015",

month = mar,

day = "1",

doi = "10.1038/ki.2014.425",

language = "English (US)",

volume = "87",

pages = "502--508",

journal = "Kidney International",

issn = "0085-2538",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder

T2 - A commentary from a Kidney Disease: Improving Global Outcomes controversies conference

AU - Ketteler, Markus

AU - Elder, Grahame J.

AU - Evenepoel, Pieter

AU - Ix, Joachim H.

AU - Jamal, Sophie A.

AU - Lafage-Proust, Marie Hélène

AU - Shroff, Rukshana

AU - Thadhani, Ravi I.

AU - Tonelli, Marcello A.

AU - Kasiske, Bertram L.

AU - Wheeler, David C.

AU - Leonard, Mary B.

N1 - Funding Information: MK declared having received consultancy fees and speaker honoraria from Abbvie, Amgen, Fresenius, Medice, Mitsubishi, Sanofi, Shire, and Vifor. GJE declared having received consultancy fees from Amgen, Shire, and Vifor Australia; speaker honoraria from Amgen, Sanofi and Shire. PE declared having received consultancy fees from Amgen; speaker honoraria from Amgen, Astellas, Fresenius, and Shire; research support from Amgen. JHI declared having received consultancy fees from AstraZeneca and Keryx; speaker honoraria from Shire. SAJ declared having received consultancy fees from Amgen and Sanofi; speaker honoraria from Amgen, Bayer, Sanofi/Genzyme, and Warner Chilcott/Actavis. MHLP declared having received research support from Servier. RIT declared having received consultancy fees from Fresenius and research support from Kaneka. MAT declared having received research support from Abbott Laboratories through a peer reviewed grant to the Canadian Institutes of Health Research. DCW declared having received consultancy fees from Abbvie, Amgen, Astellas, Baxter, F Hoffmann-La Roche, Janssen, Merck Sharp & Dohme, Otsuka, and Vifor; research funding from AstraZeneca/British Heart Foundation, Kidney Research UK, Medical Research Council, Healthcare Quality Improvement Partnership; speaker honoraria from Amgen and Otsuka. BLK, MBL and RS reported no relevant disclosures. Publisher Copyright: © 2014 International Society of Nephrology.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - A new definition and classification of chronic kidney disease-mineral and bone disorder (CKD-MBD) was proposed in 2005 and it was later followed by a guideline publication on this topic from Kidney Disease: Improving Global Outcomes (KDIGO) in 2009. This work recognized that CKD-MBD is a syndrome of bone abnormalities, laboratory abnormalities, and vascular calcification linked to fractures, cardiovascular disease, and mortality. Because of limited data at the time of the original guideline systematic review, many of the recommendations were cautiously vague. KDIGO convened a Controversies Conference in October 2013 to review the CKD-MBD literature published since the 2009 guideline. Specifically, the objective of this conference was to determine whether sufficient new data had emerged to support a reassessment of the CKD-MBD guideline and if so to determine the scope of these potential revisions. This report summarizes the results of these proceedings, highlighting important new studies conducted in the interval since the original KDIGO CKD-MBD guideline.

AB - A new definition and classification of chronic kidney disease-mineral and bone disorder (CKD-MBD) was proposed in 2005 and it was later followed by a guideline publication on this topic from Kidney Disease: Improving Global Outcomes (KDIGO) in 2009. This work recognized that CKD-MBD is a syndrome of bone abnormalities, laboratory abnormalities, and vascular calcification linked to fractures, cardiovascular disease, and mortality. Because of limited data at the time of the original guideline systematic review, many of the recommendations were cautiously vague. KDIGO convened a Controversies Conference in October 2013 to review the CKD-MBD literature published since the 2009 guideline. Specifically, the objective of this conference was to determine whether sufficient new data had emerged to support a reassessment of the CKD-MBD guideline and if so to determine the scope of these potential revisions. This report summarizes the results of these proceedings, highlighting important new studies conducted in the interval since the original KDIGO CKD-MBD guideline.

KW - CKD-MBD

KW - PTH

KW - calcium

KW - clinical practice guideline

KW - phosphate

KW - renal osteodystrophy

UR - http://www.scopus.com/inward/record.url?scp=84938416638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938416638&partnerID=8YFLogxK

U2 - 10.1038/ki.2014.425

DO - 10.1038/ki.2014.425

M3 - Article

C2 - 25651364

AN - SCOPUS:84938416638

SN - 0085-2538

VL - 87

SP - 502

EP - 508

JO - Kidney International

JF - Kidney International

IS - 3

ER -

Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: A commentary from a Kidney Disease: Improving Global Outcomes controversies conference

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this